HGH fragments refers to synthetic peptides corresponding to the C-terminal region of human growth hormone, roughly residues 176 to 191, studied for a lipolytic (fat-mobilising) effect reported to be separable from growth hormone’s classical growth-promoting and diabetogenic actions. The best-characterised member of this family is AOD9604, a modified version of the fragment carrying an additional N-terminal tyrosine, and the substantial majority of the published lipolytic research described below was conducted using this modified compound rather than the unmodified 176-191 sequence. This article reviews the structure of both forms, the proposed mechanism, the published preclinical literature, research applications and the handling requirements relevant to a laboratory setting.
What are HGH fragments?
Human growth hormone is a 191-amino-acid protein, and the compounds sold as HGH fragments correspond to its C-terminal tail. The unmodified sequence, hGH(176-191) or hGH(177-191) depending on the numbering convention used, is a 16-residue peptide with the sequence Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, stabilised by an internal disulfide bond, with a molecular weight of approximately 1,799 g/mol. AOD9604 is a closely related but chemically distinct 17-residue peptide, carrying an additional tyrosine at the N-terminus of the same core sequence; this modification was introduced for synthesis and stability reasons rather than to change the peptide’s biological target.
This distinction matters for anyone reading the published literature: the great majority of lipolytic research in this area, including every study described below, was conducted using AOD9604 specifically, not the unmodified 176-191 fragment. A direct PubMed search for the unmodified fragment by name returns essentially no lipolysis-related studies; the one paper indexed under that exact term concerns an unrelated application, enhancing nanoparticle-delivered chemotherapy uptake in a breast cancer cell line, and has no bearing on metabolic research. Suppliers and some secondary sources use “HGH fragment 176-191” and “AOD9604” interchangeably, but a technically literate reader should treat the lipolytic evidence base as belonging specifically to AOD9604.
The research programme behind this compound originated at Monash University in Melbourne in the 1990s, where researchers fragmented the hGH molecule to determine which region was responsible for its lipolytic activity, identifying the C-terminal domain as the principal driver of fat mobilisation in their experimental systems.
Mechanism of action
The proposed mechanism for AOD9604 and the related C-terminal fragment centres on adipose tissue lipid metabolism rather than on classical growth hormone receptor signalling. Receptor-binding assays reported in the published literature found that AOD9604 does not compete for the growth hormone receptor and does not induce the cell proliferation associated with intact hGH binding that receptor, a finding used to support the idea that the fragment’s effects occur through a route distinct from the pathway responsible for growth hormone’s IGF-1-generating, growth-promoting actions.
In isolated adipose tissue, AOD9604 has been reported to stimulate hormone-sensitive lipase and inhibit acetyl coenzyme A carboxylase, enzymatic changes consistent with increased lipolysis and reduced fat synthesis, broadly mirroring the direction of effect produced by intact hGH in the same tissue. The specific receptor mediating these effects at the adipocyte has not been identified in the primary literature; no study has named a confirmed binding partner for the fragment itself. Beta-3 adrenergic receptors (β3-AR) have been examined as a candidate pathway, since this receptor is known to mediate lipolysis in rodent adipose tissue, but a direct mechanistic study using β3-AR knockout mice, described below, concluded that the lipolytic actions of both intact hGH and AOD9604 were not mediated directly through this receptor, even though chronic treatment increased β3-AR expression. Researchers should treat the mechanism as an area of continuing characterisation rather than a fully resolved receptor pathway, and should be cautious about mechanistic claims that go beyond what the primary papers themselves conclude.
What the research shows
The foundational metabolic characterisation was reported by Ng and colleagues in Hormone Research in 2000, using obese Zucker (fa/fa) rats. Daily oral treatment with AOD9604 at 500 micrograms per kilogram body weight for 19 days was reported to reduce body weight gain by more than 50% relative to controls, with increased lipolytic activity measured in adipose tissue. Using euglycaemic clamp techniques, the authors reported that, in contrast to chronic treatment with intact hGH, AOD9604 showed no adverse effect on insulin sensitivity in the treated animals (Ng et al., 2000, PubMed).
A related study by Heffernan and colleagues, published in the International Journal of Obesity in 2001, examined fat oxidation and weight loss in obese mice following chronic treatment with either intact human growth hormone or the modified C-terminal fragment. The investigators reported increased fat oxidation alongside weight loss in both treatment groups, and separately reported that AOD9604 did not compete for the growth hormone receptor in binding assays, unlike intact hGH, supporting the proposed dissociation between the fragment’s metabolic effects and the classical growth hormone receptor pathway.
The mechanistic question of receptor involvement was examined directly by Heffernan and colleagues in a second 2001 paper, published in Endocrinology, using obese mice alongside β3-adrenergic receptor knockout mice. The study reported that chronic treatment with either intact hGH or its lipolytic fragment produced lipid metabolism effects in both wild-type and β3-AR knockout animals, leading the authors to conclude that the lipolytic actions of hGH and AOD9604 were not mediated directly through the β3-adrenergic receptor, although both treatments were reported to increase β3-AR expression over the treatment period, which the authors proposed might contribute to greater lipolytic sensitivity over time (Heffernan et al., 2001, PubMed).
Beyond these core preclinical papers, a small number of early-phase human studies of AOD9604 were reported as part of its development as a candidate anti-obesity compound, examining safety and metabolic parameters in human volunteers; researchers wanting that clinical detail should consult the primary trial publications directly, since this article’s scope is the preclinical and mechanistic literature summarised above. Readers should also note that no substantive independent lipolytic research exists for the unmodified 176-191 fragment as distinct from AOD9604, a gap worth bearing in mind when evaluating supplier claims that treat the two as interchangeable.
Research applications
In the laboratory, AOD9604 and the related C-terminal fragment are used mainly as tools for studying lipid metabolism and adipose tissue biology independent of growth hormone receptor signalling. Isolated adipose tissue and adipocyte models are used to examine hormone-sensitive lipase activity, acetyl CoA carboxylase inhibition, and lipolytic response to the fragment, often in direct comparison with intact hGH to characterise which effects are shared and which diverge.
Rodent models of obesity, including the Zucker fatty rat and diet-induced obese mouse models used in the studies above, remain the standard approach for examining body weight, fat oxidation and insulin sensitivity outcomes following chronic fragment administration. Receptor-binding and knockout mouse studies, following the β3-adrenergic receptor knockout design used in the mechanistic work described above, are used to test candidate receptor pathways and to rule out mechanisms not responsible for the observed lipolytic effect.
Because AOD9604 does not engage the growth hormone receptor in the assays reported to date, it is also used as a comparative tool in growth hormone receptor pharmacology research more broadly, allowing researchers to separate growth hormone’s receptor-dependent, IGF-1-linked actions from receptor-independent metabolic effects attributed to its C-terminal domain.
Purity, storage and handling
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing HGH Fragments should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and those comparing suppliers should look for the same documentation from any best peptides supplier UK they consider.
Reversed-phase HPLC separates the target peptide from truncated or deletion sequences and residual synthesis by-products, and research-grade material is commonly specified at 98% purity or above. Mass spectrometry alongside HPLC confirms identity and, importantly, distinguishes AOD9604 from the unmodified 176-191 fragment, since the two differ by a single N-terminal tyrosine residue and therefore by a small but measurable difference in molecular weight; a batch-specific certificate of analysis should state clearly which form a given product contains. This batch-level documentation, rather than a generic product datasheet, is what links a physical vial to those results and allows unexpected experimental data to be traced back to a defined lot and a confirmed identity.
Lyophilised material should be kept sealed at -20°C for long-term storage, protected from moisture and light, and brought to room temperature before opening so that condensation does not enter the vial. Once reconstituted in sterile water or an appropriate buffer, the peptide should be divided into single-use aliquots, held at 2–8°C only for short working periods, and otherwise kept frozen, since repeated freeze–thaw cycles risk reducing the integrity of the internal disulfide bond. The phenylalanine and, where present, the added tyrosine residues are susceptible to photo-oxidation, so amber vials or foil-wrapped storage are sensible precautions during handling. Published reconstituted-stability data specific to these fragments are limited in the open literature, so laboratories should validate their own working window empirically, for example by comparing HPLC profiles of fresh and aged aliquots.
Frequently asked questions
What are HGH fragments used for in research?
They are used mainly as tools for studying lipolysis and adipose tissue lipid metabolism, examined in isolated fat tissue preparations and in rodent models of obesity, with particular interest in effects reported to occur independently of the classical growth hormone receptor pathway. It is not evaluated here as a treatment, and this article makes no claims about use in humans.
Is HGH Fragment 176-191 the same as AOD9604?
Not exactly. AOD9604 carries an additional N-terminal tyrosine that the unmodified 176-191 sequence does not. The two are closely related and often sold or discussed interchangeably, but nearly all of the published lipolytic research specific to this region of growth hormone was conducted using AOD9604, not the plain 176-191 fragment.
What receptor do HGH fragments act through?
No specific adipocyte receptor for the fragment has been confirmed in the primary literature. Published research has ruled out both the classical growth hormone receptor and direct beta-3 adrenergic receptor-mediated action as the lipolytic mechanism, even though chronic treatment was reported to increase beta-3 adrenergic receptor expression, leaving the precise mechanism an area of ongoing characterisation.
How should HGH fragments be stored once reconstituted?
Reconstituted material should be divided into single-use aliquots, kept refrigerated only briefly and otherwise frozen, protected from light, and not subjected to repeated freeze–thaw cycles. Because published stability data are limited, laboratories should confirm their own storage window empirically, for example with HPLC comparisons of fresh and aged aliquots.
The HGH fragments discussed in this article are supplied for in-vitro and in-vivo laboratory research only. They are not intended for human or veterinary use, and nothing in this article should be read as guidance on administration to people or animals.
